Press Releases for HGSI

Press Releases
Ridgewater Equity Reviews the Following Equities Human Genome Sciences Inc., Intuit Inc., Advanced Battery Technologies, Linn Energy LLC, Intel Corp. and Allos Therapeutics Inc.
2009 Mid-Atlantic Bio Conference Attracts Record Number of Bioscience Companies
Howard Dean to Speak at the 2009 Mid-Atlantic Bio Conference
Biotech Cools Off in August But Capital Markets Remain Positive
Biotech Cools Off in August But Capital Markets Remain Positive
Stocks This Morning: Dragon Capital Group - August 26, 2009
BioMed Realty Trust Commemorates Five-Year Anniversary As a Public Company ; Ringing NYSE Closing Bell(R) Today; Provides Tenant Update
Biotech Hot in July Driven By Positive Drug Data and Acquisitions
Human Genome Sciences Announces Closing of Public Offering
StockPreacher.com Issues Trading Outlook for Hard to Treat Diseases Inc.
Breaking News: SUWN - July 30, 2009
Human Genome Sciences Announces Pricing of Public Offering of Common Stock
Human Genome Sciences Announces Proposed Public Offering of Common Stock
Human Genome Sciences Announces Second-Quarter 2009 Financial Results and Key Developments
Human Genome Sciences Announces New Order for Raxibacumab (ABthrax(TM)) from U.S. Government
Benlysta shows promise in treating lupus
Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus
Reminder - Human Genome Sciences to Host Conference Call to Discuss Top-Line Phase 3 Results for BENLYSTA(TM) (Formerly LymphoStat-B(R)) in Systemic Lupus Erythematosus
Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus
Data Published in The New England Journal of Medicine Support Use of Raxibacumab (ABthrax(TM)) for the Treatment of Inhalation Anthrax
Human Genome Sciences to Host July 20 Conference Call to Discuss Top-Line Phase 3 Results for Benlysta(TM) (Formerly Lymphostat-B(R)) in Systemic Lupus Erythematosus
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Piper Jaffray Conference
Human Genome Sciences Announces Completion of Enrollment in Phase 2b Monthly-Dosing Trial of Albuferon(R)
Human Genome Sciences Reports Positive Long-Term Data for BENLYSTA(TM) (Formerly LymphoStat-B(R)) in Patients With Active Systemic Lupus Erythematosus
FYI From Human Genome Sciences: GlaxoSmithKline Study Shows GSK's Novel Diabetes Treatment Syncria(R) (Albiglutide) Improves Glucose Control, Reduces Weight
Human Genome Sciences Submits Biologics License Application to FDA for ABthrax(TM)
Human Genome Sciences and Novozymes Announce Amendment to Albumin Fusion License Agreement
Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments
Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C
David R. King to Receive MAC Alliance Entrepreneurial Award
WallStSense.Com Free Research Report for Shareholders of XRAY, HGSI, FULT and CEDC
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Citi Conference - Mar 27 2009 8:39AM
QLT Names Kathryn Falberg to the Board of Directors
Human Genome Sciences and Morphotek(R), Inc. Announce Collaboration to Discover, Develop and Commercialize Antibodies for Oncology and Immunology
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Cowen Conference
Human Genome Sciences to Sponsor Conference Call
Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C
Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments
Human Genome Sciences to Sponsor Conference Call to Discuss Full Year 2008 Financial Results
Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes
Stock Preacher Issues Technical Trade Alerts on: HGSI, KGC, NOVL, PMCS, RFMD
Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JPMorgan Conference
FYI from Human Genome Sciences: GSK Initiates Darapladib Phase 3 Development Program
Human Genome Sciences to Sponsor Conference Call
Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Piper Jaffray Conference
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Lazard Capital Conference
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Deutsche Bank Conference
Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments
Human Genome Sciences to Sponsor Conference Call to Discuss Third Quarter 2008 Financial Results
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JMP Securities Conference
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at UBS Conference
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Robert W. Baird Conference
Human Genome Sciences Announces Process Development and Manufacturing Alliance With Hospira
Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Conference
Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial
Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung Cancer
Human Genome Sciences Announces Second Quarter 2008 Financial Results and Key Developments
Human Genome Sciences Appoints David P. Southwell to its Board of Directors
Human Genome Sciences to Sponsor Conference Call to Discuss Second Quarter 2008 Financial Results
Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Goldman Sachs Conference
Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors
Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives
Human Genome Sciences Invites Investors to Listen to Webcast of Presentations at Analyst & Investor Meeting - May 27 2008 12:59AM
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Citi Conference - May 27 2008 12:55AM
Human Genome Sciences Names Kevin P. McRaith Vice President, Hepatology Franchise - May 27 2008 12:53AM
Human Genome Sciences Appoints John L. Lamattina, Ph.D., to Its Board of Directors - Jun 1 2008 10:14PM
Human Genome Sciences Announces First Quarter 2008 Financial Results and Key Developments - Jun 1 2008 10:14PM
BellwetherReport.com Initiates Analyst Coverage on TXRH, TRID, HGSI and BIIB - May 27 2008 1:16AM
Human Genome Sciences to Sponsor Conference Call to Discuss First Quarter 2008 Financial Results
Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
Human Genome Sciences Advances Oncology Portfolio